Eisai Announces the Merger of Two Subsidiaries in Taiwan
Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) announced today the merger of two Taiwan subsidiaries, involving a manufacturing and marketing subsidiary, Eisai Taiwan Inc. (Headquarters: Taipei, Chairman and President and CEO: Yoichi Endo), and another marketing subsidiary in Taiwan, Wei-zai Co., Ltd. (Headquarters: Taipei, President: Fang-ming Chang). The surviving company is Eisai Taiwan Inc.
Eisai set up its first sales office in Taipei in 1967 and has since developed and expanded business in Taiwan, marked by the establishment of a manufacturing facility and marketing subsidiaries. Eisai's current core business in Taiwan is manufacturing and marketing of pharmaceuticals including major global products, ARICEPT, an Alzheimer's disease treatment and PARIET, a proton pump inhibitor.
Through this merger, the surviving company, Eisai Taiwan Inc. will aim at expanding marketing efforts and enhancing competitiveness in the market to improve performance in the Taiwan pharmaceutical business and provide further contributions to the benefits of patients.
[Surviving Company Outline]
[The outline of the two subsidiaries before merger and the size of the Taiwan market are attached hereto for reference]
Eisai Co., Ltd.
Corporate Communications Department
Phone 03-3817-5120 (Tokyo)
1. Outline of Eisai Taiwan Inc. and Wei-zai Co., Ltd. before merger